Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01800032 · ClinicalTrials.gov registry record
PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)
A clinical trial of Neurofibromatosis 1 and Plexiform Neurofibroma, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT01800032: Completed study of Neurofibromatosis 1 and Plexiform Neurofibroma, sponsored by UNC Lineberger Comprehensive Cancer Center.
NCT01800032 is a study of Neurofibromatosis 1 and Plexiform Neurofibroma that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 30 participants, below the 1,034-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01800032, a study of Neurofibromatosis 1 and Plexiform Neurofibroma, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This prospective pilot study is designed to provide preliminary data on the use of Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Imaging (FDG-PET-MRI) in patients with neurofibromatosis-1 (NF1) associated optic glioma and plexiform neurofibroma (PN). Subjects will undergo FDG-PET-MRI scans in place of standard of care imaging at 0 and 12 months, unless more frequent imaging is clinically indicated. Subjects and their family caregivers will also undergo serial interviews and complete questionnaires related to the psychosocial aspects of NF1.
Primary Outcome
Ratios of SUVmax values within a group of patients who all have progressive disease
Conditions Studied
Study Locations (1)
North Carolina
- University of North Carolina-Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-01-16 |
| Est. Completion | 2019-12-05 |
What the finished NCT01800032 record still lists
NCT01800032 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,034-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Neurofibromatosis 1 appearing as the primary indexed condition, and to 0 interventions.
NCT01800032 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01800032 about?
NCT01800032 is a clinical study titled "PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)". This prospective pilot study is designed to provide preliminary data on the use of Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Imaging (FDG-PET-MRI) in patients with neurofibromatosis-1 (NF1) associated optic glioma and plexiform neurofibroma (PN). Subjects will undergo FDG-P...
What is the current status of trial NCT01800032?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2013-01-16. Estimated completion is 2019-12-05.
What conditions does trial NCT01800032 study?
This clinical trial studies the following conditions: Neurofibromatosis 1, Plexiform Neurofibroma, Optic Glioma.
Who is sponsoring clinical trial NCT01800032?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01800032 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01800032's enrollment target sits among peer trials
30 20th of 24 higher than 4 of 24 other Neurofibromatosis 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neurofibromatosis 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
RECRUITING · NA
-
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
RECRUITING · NA
-
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
RECRUITING
-
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
RECRUITING · Phase 1
-
Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy
RECRUITING · NA
-
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI